arrow
M

Momoko Nishikori

kyoto university
H指数:26
被引数:2,637

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: the phase II NCCH1903/ATTACK trial

阿特珠单抗治疗复发/难治性结外NK/T细胞淋巴瘤:NCCH1903/ATTACK II期试验

2026-05-220
OAAI
Prolonged Cytokine Release Syndrome Is Associated With Hypofibrinogenemia After CD19-Directed CAR T-Cell Therapy in Adult Patients With Relapsed/Refractory Lymphoma

成人复发/难治性淋巴瘤患者接受CD19靶向CAR T细胞治疗后,长期细胞因子释放综合征与低纤维蛋白原血症相关

2026-05-210
OAAI
Impact of the diagnosis-to-treatment interval on the survival of patients with CD5-positive diffuse large B-cell lymphoma

CD5阳性弥漫大B细胞淋巴瘤患者诊断至治疗间隔对其生存的影响

2026-04-250
OAAI
Three-year follow-up of epcoritamab therapy in Japanese patients with relapsed/refractory follicular lymphoma in EPCORE NHL-3

EPCORE NHL-3研究中日本复发性/难治性滤泡性淋巴瘤患者接受epcoritamab治疗的三年随访

2026-01-010
OAAI
Preliminary analysis of a multicenter study of Pola-R-CHP in untreated Japanese patients with DLBCL (POLASTAR)

POLASTAR研究:Pola-R-CHP在未经治疗的日本DLBCL患者中的多中心初步分析

2025-12-010
OA
Treatments and Outcomes of Newly Diagnosed CD5-Positive Diffuse Large B-Cell Lymphoma: A Multi-Institutional Observational Study
2025-02-120
OA
KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia
LEUKEMIA
IF13.4
2024-04-181
PRE
Clinical Impact of Cytokine Release Syndrome on Prolonged Hematotoxicity after Chimeric Antigen Receptor T Cell Therapy: KyoTox A-Score, a Novel Prediction Model

细胞因子释放综合征对嵌合抗原受体T细胞治疗后长期血液毒性的临床影响: KyoTox A评分,一种新的预测模型

2024-04-018
OAAI